1. Introduction

Arava is a synthetic oral disease-modifying antirheumatic drug (DMARD) primarily indicated for the management of moderate to severe rheumatoid arthritis (RA). It is also used off-label in other inflammatory arthritides such as psoriatic arthritis and certain forms of vasculitis. Its mechanism, safety profile, and complex pharmacokinetics require careful consideration by healthcare professionals.

2. Mechanism of Action

Leflunomide (active metabolite: teriflunomide) is an isoxazole derivative with immunomodulatory and antiproliferative properties. Its principal action is the inhibition of dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme critical for de novo pyrimidine synthesis. This blockade reduces the proliferation of lymphocytes and other immune cells, thereby attenuating inflammatory processes in autoimmune diseases.

• Anti-inflammatory effects: In addition to DHODH inhibition, leflunomide modulates cytokine production (e.g., TNF-α, IL-6), inhibits T-cell activation, and reduces synovial inflammation.
• Evidence Base: Multiple randomized controlled trials (RCTs) have demonstrated its efficacy in reducing RA disease activity, slowing radiographic progression, and improving physical function (Brennan et al., Ann Rheum Dis 2005; Felson et al., Arthritis & Rheumatology 2011).

3. Indications

• Primary: Rheumatoid arthritis (RA)
• Secondary: Psoriatic arthritis, reactive arthritis, and certain vasculitides (off-label use)

4. Dosage and Administration

• Loading dose: 100 mg twice daily for 2–3 days (total 200–300 mg), followed by a maintenance dose of 20 mg once daily.
• Formulations: Available as film-coated tablets (10 mg, 20 mg) and in blister packs (100 mg total).
• Titration: Dose adjustments may be required based on tolerability, efficacy, and laboratory findings.

Pharmacist’s Note:

• The loading dose is crucial for achieving therapeutic blood levels rapidly.
• Monitor for delayed onset of clinical benefit (typically 6–12 weeks).

5. Efficacy & Monitoring

• Clinical response: May take several weeks to months; RA Disease Activity Score (DAS28) should be reassessed at regular intervals.
• Laboratory monitoring: Baseline and periodic CBC, LFTs, creatinine, and urinalysis are recommended due to potential hepatotoxicity and hematologic effects.

6. Adverse Effects

a) Hematologic

• Leukopenia, thrombocytopenia, anemia (monitor CBC every 1–2 weeks initially)
• Risk of severe infections due to immunosuppression

b) Hepatic

• Elevated transaminases; rare cases of fulminant hepatic failure
• Baseline and periodic LFTs are mandatory

c) Neurologic

• Peripheral neuropathy (tingling, burning, weakness)
• Headache, dizziness

d) Pulmonary

• Interstitial lung disease (rare but serious; monitor for dyspnea, cough, fever)

e) Dermatologic

• Severe cutaneous reactions: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN)
• Risk of hypersensitivity syndrome (fever, rash, lymphadenopathy)

f) Other

• Gastrointestinal upset, increased cholesterol/triglycerides
• Potential for hepatotoxicity and bone marrow suppression

7. Drug-Drug Interactions

Leflunomide has a narrow therapeutic index and significant interaction potential:

• Hepatotoxic drugs: NSAIDs (ibuprofen, naproxen), acetaminophen (especially >2g/day), sulfa antibiotics, isoniazid
• Immunosuppressants: Azathioprine, cyclosporine, tacrolimus, mycophenolate
• Anticonvulsants: Carbamazepine, phenytoin, valproic acid (may accelerate clearance)
• Statins: Increased risk of myopathy
• Hormonal therapies: Contraceptive efficacy may be reduced

Pharmacist’s Action:

• Review all medications, including OTCs and supplements.
• Consider alternative analgesics/antimicrobials if possible.

8. Contraindications & Precautions

• Absolute contraindications: Severe hepatic impairment, concurrent use with teriflunomide or other DMARDs (e.g., methotrexate), pregnancy
• Relative contraindications: History of hypersensitivity, bone marrow suppression, severe renal/hepatic disease

9. Pregnancy & Lactation

• Teratogenicity: High risk of major birth defects if used during pregnancy.
• Contraception required: Women of childbearing potential must use effective contraception for at least 2 years after stopping Arava (up to 14 days post-discontinuation in some protocols).
• Breastfeeding: Contraindicated; leflunomide is excreted in breast milk.

10. Storage & Disposal

• Store at room temperature, away from moisture and light.
• Keep out of reach of children.
• Dispose of unused medication via pharmacy take-back programs or as per DEA guidelines.

11. Special Considerations for Pharmacists

• Patient counseling: Emphasize the importance of adherence to loading dose, regular monitoring, and reporting adverse effects.
• Drug interactions: Proactively review all concurrent medications.
• Pregnancy planning: Counsel women on contraception and the long elimination period (up to 2 years).
• Monitoring: Ensure patients have baseline labs before starting; schedule follow-up for CBC/LFTs.

12. References & Guidelines

• American College of Rheumatology (ACR) 2022 guidelines on RA management
• FDA prescribing information: Leflunomide (Arava)
• British Society for Rheumatology (BSR) recommendations

Summary for Pharmacists

Arava (leflunomide) is a potent DMARD with proven efficacy in RA, but its use requires vigilant monitoring due to significant risks of hepatotoxicity, bone marrow suppression, and teratogenicity. Pharmacists play a critical role in medication reconciliation, patient education, and coordination of care to minimize adverse outcomes and optimize therapeutic benefit.

Always consult the latest local guidelines and individual patient factors before initiating or modifying therapy.